
    
      As an investigator initiated and conducted, multicentre, ambulance-delivered, prospective,
      randomised, open-label, blinded outcome (PROBE) study. INTERACT4 aims to evaluate the effects
      of functional outcome according to an ordinal analysis of the full range of scores on the
      mRS, the safety in all randomised patients; reperfusion treatment (thrombolysis and/or
      thrombectomy) related symptomatic ICH (sICH, according to standard definitions), infarct
      size, the time to and overall rate of reperfusion treatment in AIS patients; hematoma volume
      and early expansion in ICH.
    
  